RNCohortJournal of infusion nursing : the official publication of the Infusion Nurses Society2023

Prevalence of Hospital-Onset Bacteremia Pre- and Post-Implementation of a Needleless Blood Sampling Device From Existing Peripheral Catheters.

Kalvin C Yu, ChinEn Ai, Molly Jung and 4 others

PMID 37490579

WHAT IT FOUND

Hospital-onset bacteremia rates dropped significantly at one community hospital after adopting a needleless blood sampling device, but showed no significant change at an oncology center.

Overall, the device was not associated with increased infection risk compared to control hospitals.

Key findings

01In adjusted analyses, hospital-onset bacteremia prevalence was significantly lower after device implementation at one hospital, but not significantly different at the second hospital or control facilities.

02Rates of commensal events (contaminated cultures) were significantly lower after device implementation at both hospitals using the device, while control hospitals saw no significant change.

03The study did not find evidence that the needleless device increased the aggregate risk of bacteremia events.

STILL TO COME

How it was doneWhat they foundWhat it means for RNs

Read the rest of this summary

You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.

Already have one?

What it does not show

The study is based on only two hospitals implementing the device, limiting generalizability. The two hospitals had higher baseline bacteremia rates than the control hospitals before the device was introduced. The analysis was at the facility level, so it cannot determine if the reduction in events was directly caused by the device or other concurrent changes in nursing practice or hospital protocols. The study period overlapped with the COVID-19 pandemic, which may have influenced infection rates and hospital workflows despite statistical adjustments.

Declared interests

All authors are employed by Becton, Dickinson and Company (BD), which owns VelanoVascular, the manufacturer of the PIVO device. BD provided financial support for the study and editorial assistance.

The easy way to misread this

Do not conclude that the device directly caused the reduction in bacteremia or contaminated cultures. This was an observational study at the facility level, meaning other changes in hospital practice during the same period could explain the results, and the study was not designed to isolate the specific effect of the device on individual patients.

Read it on PubMed →